Mobile website
Archive > Volume 30 Issue 9 > 2023,30(9):745-753. DOI:10.3872/j.issn.1007-385X.2023.09.001 Prev Next
Expert Forum
Dendritic cells in the clinical treatment of solid tumors：turning the corner
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Tumor immunocytotherapy has shown promising clinical prospects. Recognition of tumor antigens by dendritic cells (DCs) is a critical initiating step in immune response. After capturing tumor antigens, DCs differentiate into mature cells and present the antigen signals to immune cells such as CD4+ T and CD8+ T cells in the lymph nodes, thereby stimulating an anti-tumor effect. This approach holds great potential for tumor treatment, especially for solid tumors. However, the complex structure of the solid tumor microenvironment and unclear mechanisms of DC and T/B cell immune response present significant challenges in front of us; therefore, the key theoretical and technological breakthroughs have not been achieved yet. Despite the advantages demonstrated by precise cellular immunotherapy such as CAR-T cells, antigen selection remains a bottleneck in treating solid tumors. DC-based therapeutic vaccines have shown promising efficacy and safety in clinical trials. With further elucidation of the important mechanisms of DCs in the TME, researchers have refocused on the anti-tumor effects of DCs. This has prompted the clinical transformation of DC combination therapies and synthetic biology vaccines for the treatment of solid tumors. Currently, DC-based clinical treatments for solid tumors are entering a new stage. This article provides a comprehensive review of the progress in clinical research on DC-based therapy for solid tumors, the types of DCs in TME and their anti-tumor mechanisms, engineered DC vaccines, as well as the existing challenges and coping strategies.
Keywords:
Project Supported:
Clc Number:
